^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1)

    i
    Other names: NTRK1, MTC, TRK, TRKA, Neurotrophic tyrosine kinase, receptor, type 1
    2d
    Infantile Congenital Nevus With Atypical Proliferative Nodules and NTRK Gene Fusion. (PubMed, J Cutan Pathol)
    This case highlights the role of TPR::NTRK1 fusion in driving abnormal melanocyte proliferation and the potential contribution of MCL1 amplification to tumor progression. These findings provide insights into the genetic underpinnings of APN in CMN and suggest potential therapeutic targets for high-risk lesions.
    Journal
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • MCL1 (Myeloid cell leukemia 1) • PRAME (Preferentially Expressed Antigen In Melanoma) • MLANA (Melan-A) • NTRK (Neurotrophic receptor tyrosine kinase) • CD99 (CD99 Molecule)
    |
    NTRK fusion
    2d
    Larotrectinib in patients with tropomyosin receptor kinase fusion solid tumors in Spain (SPAINTRK). (PubMed, Eur J Cancer)
    Larotrectinib evoked broad and durable antitumor activity in a plethora of solid tumors with NTRK fusions. Safety profile was consistent with that of clinical trials, even after long-term administration. While NGS use is increasing, broader access is needed.
    Journal
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    NTRK fusion
    |
    Vitrakvi (larotrectinib)
    9d
    Protein kinase-related tumors in the pediatric population : Updated review on an emerging group with emphasis on the more rarely involved kinases. (PubMed, Pathologie (Heidelb))
    This review provides updates to understand the currently known spectrum of PK-related lesions, with emphasis on those occurring more rarely, to aid proper diagnoses and treatment. The aim is to contribute to a better holistic classification.
    Review • Journal
    |
    ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • CD34 (CD34 molecule) • NTRK (Neurotrophic receptor tyrosine kinase)
    10d
    NTRK-rearranged soft tissue sarcoma that originated from the head and neck with a robust response to the TRK inhibitor larotrectinib. (PubMed, Int Cancer Conf J)
    Concurrent comprehensive genome profiling (FoundationOne® CDx) confirmed the LMNA-NTRK1 fusion, and treatment with the TRK inhibitor larotrectinib was started. With larotrectinib treatment, the tumor shrank in size at an early stage, and the response has been maintained for > 2 years.
    Journal
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • LMNA (Lamin A/C) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    NTRK positive • NTRK fusion
    |
    FoundationOne® CDx
    |
    Vitrakvi (larotrectinib)
    15d
    Larotrectinib in Adjuvant and First-Line Treatment for Metastatic NTRK Fusion Colon Cancer. (PubMed, Asia Pac J Clin Oncol)
    At the time of this clinical case report, therapy is ongoing for 21 months without any signs of further disease progression. This study demonstrates the efficacy and safety of larotractinib as both adjuvant therapy and first-line therapy in a complex clinical case of colon cancer against the background of severe concomitant pathology, when chemotherapy is contraindicated.
    Journal
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    NTRK fusion
    |
    Vitrakvi (larotrectinib)
    16d
    AB-106-C205: Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion (clinicaltrials.gov)
    P2, N=14, Terminated, Nuvation Bio Inc. | N=40 --> 14 | Recruiting --> Terminated; The study was discontinued early by the Sponsor for business reasons on 06 Dec 2024
    Enrollment change • Trial termination • Pan tumor
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)
    |
    Ibtrozi (taletrectinib)
    28d
    STARTRK-2: Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (clinicaltrials.gov)
    P2, N=534, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Dec 2025 --> May 2026 | Trial primary completion date: Dec 2025 --> May 2026
    Trial completion date • Trial primary completion date • Pan tumor
    |
    ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)
    |
    ALK rearrangement • ROS1 rearrangement
    |
    Xalkori (crizotinib) • Rozlytrek (entrectinib)
    28d
    DNA And RNA-Based Next-Generation Sequencing For Companion Diagnostic Rearrangement Detection In Solid Tumors. (PubMed, Oncologist)
    A higher rate of CDx SV detection-most significantly for NRG1 and NTRK fusions-was observed using concurrent DNA-CGP and RNA-CGP compared to DNA-CGP alone. Our results highlight the complementary nature of these methods. Given the substantial clinical benefit of SV targeted therapies, an integrated DNA/RNA profiling strategy should be part of routine clinical care.
    Journal • Next-generation sequencing • Companion diagnostic
    |
    BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • FGFR2 (Fibroblast growth factor receptor 2) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • NRG1 (Neuregulin 1) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    NRG1 fusion • NTRK fusion
    30d
    2021-ky301: Hybrid Dose-fraction Radiotherapy for Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=78, Completed, Anhui Provincial Hospital | Recruiting --> Completed
    Trial completion
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)
    |
    BRAF V600E • KRAS G12C • BRAF V600 • MET exon 14 mutation • KRAS G12
    30d
    THE INFLUENCE OF AGE-INDEPENDENT SOMATIC DRIVER ALTERATIONS ON CLINICAL OUTCOMES IN PEDIATRIC AND YOUNG ADULT THYROID CANCER. (PubMed, Eur Thyroid J)
    While prognosis steadily improved with age, mutation status remained the dominant factor determining outcomes. Somatic drivers offer prognostic insights independent of age in paediatric and young adult DTC, establishing a molecular framework for precision risk stratification that complements traditional clinical staging and age-based assessments.
    Clinical data • Journal
    |
    BRAF (B-raf proto-oncogene) • RET (Ret Proto-Oncogene) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • RAS (Rat Sarcoma Virus) • DICER1 (Dicer 1 Ribonuclease III)
    |
    BRAF V600E • BRAF V600 • RET fusion • RAS mutation
    1m
    An Unusual High-Grade Sarcoma of the Kidney with TPM4::NTRK1 Fusion, CDKN2A/B Deletion, SDHD and NOTCH3 Variants: The First Case Report in Pediatric Population. (PubMed, Fetal Pediatr Pathol)
    Based on these molecular findings, the diagnosis was confirmed as an NTRK-rearranged high-grade sarcoma with an unusual histomorphological phenotype. This case highlights novel molecular characteristics of NTRK-rearranged high-grade sarcoma and underscores the critical role of comprehensive molecular profiling in diagnosing challenging cases.
    Journal
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • NOTCH3 (Notch Receptor 3) • NTRK (Neurotrophic receptor tyrosine kinase) • SDHD (Succinate Dehydrogenase Complex Subunit D) • TPM4 (Tropomyosin 4)
    |
    CDKN2A deletion • NTRK fusion
    1m
    KDM3B promotes neural invasion in colorectal cancer through TrkA upregulation by inhibiting H3K9 dimethylation. (PubMed, iScience)
    The results demonstrated that overexpression of KDM3B in CRC could inhibit H3K9me2, which in turn contributed to the upregulation of TrkA, enabling binding of nerve growth factor (NGF) to it and ultimately inducing CRC NI. The present study reveals the intrinsic mechanism of NI in CRC, which lays a solid theoretical foundation for using KDM3B as a prognostic indicator and therapeutic target for CRC.
    Journal
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1)